Proteome Sciences plc (AIM:PRM)

Market Cap	6.07M -54.4%
Revenue (ttm)	4.53M +12.2%
Net Income	-3.33M
EPS	-0.01
Shares Out	350.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,221
Average Volume	212,006
Open	1.660
Previous Close	1.730
Day's Range	1.660 - 1.840
52-Week Range	1.300 - 4.500
Beta	0.20
RSI	37.38
Earnings Date	Apr 2, 2026

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling p...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1993
• Employees: 36
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PRM

Financial Performance

In 2024, Proteome Sciences's revenue was 4.89 million, a decrease of -2.80% compared to the previous year's 5.03 million. Losses were -3.41 million, 39.4% more than in 2023.